Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Selinexor is an oral inhibitor of the nuclear export protein exportin 1. Preclinical studies demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors (PI) through suppression of NF-κB signaling and nuclear retention of tumor suppressor proteins. We tested selinexor i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Bahlis, Nizar J., Sutherland, Heather, White, Darrell, Sebag, Michael, Lentzsch, Suzanne, Kotb, Rami, Venner, Christopher P., Gasparetto, Cristina, Del Col, Aldo, Neri, Paola, Reece, Donna, Kauffman, Michael, Shacham, Sharon, Unger, T. J., Jeha, Jacqueline, Saint-Martin, Jean-Richard, Shah, Jatin, Chen, Christine
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2018
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6302280/
https://ncbi.nlm.nih.gov/pubmed/30352784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-06-858852
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars